Figure 9
From: Targeted therapy against Bcl-2-related proteins in breast cancer cells
Effect of antisense Bcl-2 oligodeoxynucleotides on splenomegaly development and serum IL-12 levels in athymic mice. (a) Segment of spleen from a mouse with splenomegaly after treatment with antisense (AS) Bcl-2 oligodeoxynucleotides (ODNs), and segments from untreated (control) and synthetic CpG AS Bcl-2 ODN-treated mice. (b) Comparison of splenic weight among mice treated with AS Bcl-2 ODNs, synthetic CpG AS Bcl-2 ODNs, and control mice. (c) Increased serum levels of IL-12 were observed in mice treated with AS Bcl-2 ODNs, compared with those treated with synthetic CpG AS Bcl-2 ODNs, and with control mice. Each point represents the mean of the three mice in each group. Error bars indicate SD. The data presented are from three independent experiments.